AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01143701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADHD Collaborative
Description: The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the AAP guidelines.
Study NCT00569894 — intervention group
Intervention type: BIOLOGICAL
Intervention: TIV (Injection)
Description: One or two injections of TIV depending on previous status.
Study NCT02777320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
Study NCT02777320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
Study NCT00569894 — intervention group
Intervention type: OTHER
Intervention: Unvaccinated Control
Description: no vaccine
Study NCT03421769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EA and AMLK
Description: A 7-9mm diameter corneal epithelial tissue will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
Study NCT03421769 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LA and AMLK
Description: A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
Study NCT04136847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SkinPen Precision
Description: Surgical instrument motors and accessories/attachments/Hydrogel
Study NCT01700439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDWARDS INTUITY valve
Description: Surgical replacement of the aortic valve with the EDWARDS INTUITY valve.
Study NCT01842503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GET 73
Description: 300 mg tid on 3 days cycle
Study NCT01842503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inactive ingredients capsule
Description: 3 capsules tid on 3 days cycle
Study NCT01289015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAFT-600 ( naftin 2 % gel )
Description: Topical; applied once daily for two weeks
Study NCT01289015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical; applied once daily for two weeks
Study NCT01281410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory Muscle Training with Respifit (5 times per week)
Study NCT01281410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: Inspiratory muscle training with a device named Respifit for patients receiving a hematopoetic stem cell transplantation (till 30 days after their transplantation)
Study NCT01791907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured education in carbohydrate counting
Study NCT01791907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured education in healthy food choices and low glycemic index
Study NCT03027583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 6 weeks daily oral intake of a probiotic strain.
Study NCT03027583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 weeks daily oral intake of placebo.
Study NCT00039988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Description: 20 mg administered subcutaneously daily
Study NCT00039988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: 2 mg or 4 mg oral capsules taken daily
Study NCT01859546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short message service
Description: Short message service reminders on cell phones in improving the compliance of subsequent visits for routine immunization for children
Study NCT00824837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Larger pore haemodialysis membrane
Description: Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
Study NCT00039988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol placebo
Description: Oral placebo capsules will be taken daily
Study NCT00824837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Larger pore haemodialysis membrane
Description: Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
Study NCT00824837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard haemodialysis membrane
Description: Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
Study NCT00824837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard haemodialysis membrane
Description: Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
Study NCT02079818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penumbra Ruby Coil System
Description: The Penumbra Ruby™ Coil is a new generation of detachable coils developed by Penumbra Inc. This coil system is specifically designed for the occlusion of aneurysms and vessels that is equivalent to standard platinum coils. This system consists of: an implantable Coil attached to a Detachment Pusher as well as a Detachment Handle. The Detachment Pusher is comprised of a shaft with a radiopaque positioning marker, a Distal Detachment Tip, and a pull wire. The Detachment Handle is used to detach the Coil Implant from the Detachment Pusher. The Penumbra Ruby Coil is designed for endovascular embolization in the peripheral vasculature. Intended users for this device are physicians who have received appropriate training in interventional radiology and endovascular intervention.
Study NCT02817399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Description: Electrical stimulation that cause muscle contraction while walking
Study NCT02817399 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuro-muscular electrical stimulation
Description: Electrical stimulation that cause muscle contraction in a stationary position
Study NCT02817399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active exercises
Description: Subjects will receive training exercise according to ACL reconstruction protocol
Study NCT02817399 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active exercises
Description: Subjects will receive training exercise according to ACL reconstruction protocol
Study NCT01264601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: Age appropriate dose of seasonal Trivalent Influenza Vaccine (TIV), either 0.25mL under age 3 or 0.5mL over the age of 3.
Study NCT01660932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01660932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega
Study NCT01587079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003
Description: PT003 MDI administered as two puffs BID for 7 days
Study NCT03583619 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: APBI
Description: Patients receive radiation to the breast tumor bed to a total dose of 40Gy/10fx/2wks, using intensity-modulated radiation therapy technique.
Study NCT03583619 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBI
Description: Patients receive radiation to the whole breast to a total dose of 43.5Gy/15fx/3wks, using intensity-modulated radiation therapy technique.
Study NCT02457104 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Patients selected from those undergoing screening colonoscopy. During colonoscopy, stool aspirates and biopsies will be taken from the terminal ileum, cecum, and sigmoid colon.
Study NCT02457104 — intervention group
Intervention type: BEHAVIORAL
Intervention: Weight and diet questionnaire
Description: Brief questionnaire outlining weight history, type and dose of PPI, and diet.
Study NCT02549599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chat/Text Program
Description: Participants will receive access to the Chat/Text program on the internet via computer or mobile device. The Chat/Text program involves interactive, immediate, and tailored messages (with pre-determined content) delivered by Chat/Text agents via online chat or mobile phone text. At the conclusion of the session, the participants will receive a combination-baseline and follow-up survey.
Study NCT01587079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001
Description: PT001 MDI administered as two puffs BID for 7 days
Study NCT01587079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT005
Description: PT005 MDI administered as two puffs BID for 7 days
Study NCT01587079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium inhalation powder
Description: Taken as 1 capsule containing 18 µg of Tiotropium via the Handihaler DPI for 7 days
Study NCT02341378 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C(Low dose)
Description: TissueGene-C at 6.0x10\^6 cells
Study NCT02341378 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C(High dose)
Description: TissueGene-C at 1.8x10\^7 cells
Study NCT02661425 — intervention group
Intervention type: OTHER
Intervention: EnteraGam
Description: Serum-derived bovine immunoglobulin/protein isolate (SBI) is the nutritional ingredient in EnteraGam. SBI contains a minimum of 50% immunoglobulin. The protein isolate is a light-colored powder. Each packet contains SBI (5.0 g) and the following inactive ingredients: dextrose (5.0 g) and a trace amount of sunflower lecithin.
Study NCT00883532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: budesonide, 0.25 mg/Kg/dose every 8 hours until the infant requires FIO2 \< 30% or is extubated
Study NCT00883532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: surfactant and air (placebo)
Description: receive surfactant and air as control through endotracheal route
Study NCT02172859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lumiVida™
Study NCT02172859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03938493 — intervention group
Intervention type: OTHER
Intervention: monitoring of the endotracheal tube cuff
Description: We will enroll adult patients who will undergo endotracheal intubation for general anesthesia of head and neck surgery. The cuff pressure of the endotracheal tube will be monitored continuously during anesthesia. The cuff pressure value will be recorded and analyzed after completing the study.
Study NCT04592783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive Agents
Description: Antihypertensive medications will be initialed once BP is at predetermined threshold
Study NCT02549599 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Website Content
Description: Participants will be directed to content and information on the Planned Parenthood website. The website contains information on birth control methods, locations of Planned Parenthood health clinics, and on sexual and reproductive health more broadly.
Study NCT02549599 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Delayed Treatment
Description: Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered
Study NCT02893449 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Social adaptation
Description: Questionnaire to fill-in.~The structured program of preoperative cognitive remediation is divided in 3 parts: one interview with the patient to do a building of the subjective theories (difficulties due to the disease, hope relative to the intervention), a study meeting of the cognitive remediation possibilities and a cognitive remediation meeting with the patient. The spouse will be included in the program.
Study NCT02893449 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensive care management
Description: In this group, the structured program of the SICRPPD group will be replaced by 3 unstructured psychiatric interviews during which patients will be assessed for their perception of the disease and the upcoming surgery. This group will allow to control for the intrinsic effect of the preoperative management independently of the remediation itself.
Study NCT02893449 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Deep brain stimulation
Study NCT03174483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: nasal spray
Study NCT03174483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Nasal
Description: nasal spray
Study NCT04418765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Eptinezumab, concentrate for solution for infusion 100 mg/milliliter (mL)
Study NCT04418765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: concentrate for solution for infusion, intravenously
Study NCT01454778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel in addition to angioplasty, stenting or atherectomy Dosing will be based on the lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm\^3~Paclitaxel Dosage:~Superficial Femoral/Common Femoral: 2.4 mg/inflation of balloon\* Popliteal: 1.8 mg/inflation of balloon\* Tibial: 1.4 mg/inflation of balloon\*~* not to exceed 10mg total dose
Study NCT01882283 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea Treatment Group
Description: This intervention was a crossover trial, during which each patient experienced both placebo and tea treatment arms
Study NCT01882283 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03353727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthoptic rehabilitation
Description: Orthoptic rehabilitation using innovative mechanisms (eye tracker and tactile device) for low vision people
Study NCT02520089 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone autograft of iliac crest
Description: The investigators will take bone autograft of iliac crest of the patient and then apply into the site of pseudoarthrosis, this graft have osteogenic, osteoinductive and osteoconductive properties
Study NCT03414580 — intervention group
Intervention type: PROCEDURE
Intervention: Breath sampling for volatile organic compounds
Description: Acquisition of exhaled breath sample in exhaled air to be analysed by gas chromatography-mass spectrometry
Study NCT03214484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: By comparing the evolution of the visual acuity curves.
Description: By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
Study NCT03214484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: By comparing the evolution of the curves.
Description: By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
Study NCT01355705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: 40, 60, or 80 mg/m2 intravenous (IV)
Study NCT01355705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 15 mg daily by mouth
Study NCT01355705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg weekly by mouth
Study NCT01355705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81 or 325 mg daily by mouth
Study NCT01355705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg subcutaneous on Day 2
Study NCT03567070 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: qualitative study based on an individual clinical interview
Description: qualitative study based on an individual clinical interview
Study NCT02520089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma plus bone autograft
Description: Sample of 40 mL of peripheric blood and processed to obtain 5 mL of platelet rich plasma, and collocated into pseudoarthrosis
Study NCT01765010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Study NCT02011165 — intervention group
Intervention type: PROCEDURE
Intervention: Positioning measuring device
Description: A tennis ball in the night shirt will prevent supine position during sleep.
Study NCT01765010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Study NCT01765010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Study NCT01765010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01614132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maintenance chemotherapy (vincristin, cisplatin and CCNU)
Description: maintenance chemotherapy of maximum of 8 cycles á 42 days
Study NCT01614132 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy of the partial brain
Study NCT03068091 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Chest CT
Description: Inspiration and expiration chest CT
Study NCT03068091 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pulmonary Function Testing
Description: Measure lung function
Study NCT02971878 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)
Description: Human embryos will be cultured in media that contains 3 antioxidants (Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)) that can be found in the in vivo Environment.
Study NCT03400605 — intervention group
Intervention type: OTHER
Intervention: Infant feeding questionnaire
Description: Prospective infant feeding questionnaire administered over the telephone or in-person at 2 weeks and at 2, 4 and 6 months postpartum
Study NCT03594240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM)
Description: Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM) once daily
Study NCT03594240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in placebo group received placebo that were similar in appearance to Vitamin B complex tablets and the administered dose was as the same schedule as Vitamin B complex.
Study NCT04529356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: By using different frequency of TMS, the device can generate different effects. For low frequency, such as 1HZ, it mainly generates inhibition on the brain cortex; while high frequency (usually higher than 10HZ) can generate stimulation effects. The later one could be used to treat different central nervous disease.
Study NCT04529356 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: By using different frequency of TMS, the device can generate different effects. For low frequency, such as 1HZ, it mainly generates inhibition on the brain cortex; while high frequency (usually higher than 10HZ) can generate stimulation effects. The later one could be used to treat different central nervous disease.
Study NCT04529356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen is used as the painkiller to alleviate patients' headache before and during the clinical trial. In order to decrease the medication bias, we required these patients to only use acetaminophen instead of other non-steroid anti-inflammatory drugs. In the meantime, participants are requested to recorder the frequency and dosage of acetaminophen they used during the treatment course.